Global Myasthenia Gravis Drugs Market 2017-2021 - Product Image

Global Myasthenia Gravis Drugs Market 2017-2021

  • ID: 4039631
  • Report
  • Region: Global
  • 73 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Alexion Pharmaceuticals
  • CSL
  • Cytokinetics
  • Flamel Technologies
  • GlaxoSmithKline
  • Lupin Pharmaceuticals
  • MORE
About Myasthenia Gravis Drugs

Currently, the myasthenia gravis drugs market stands at a small size due to limited availability of approved therapies for the complete remission of the disease. However, the anticipated approval of novel drugs such as monoclonal antibodies should help market witness strong growth during the forecast period. For instance, Alexion Pharmaceuticals is currently developing a monoclonal antibody, Soliris, for the treatment of myasthenia gravis. Once launched around end 2017 or beginning of 2018, this drug is expected to be the blockbuster drug for the market.

The analysts forecast the global myasthenia gravis drugs market to grow at a CAGR of 13.16% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global myasthenia gravis drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of myasthenia gravis drugs.

The market is divided into the following segments based on geography:

- Americas
- APAC
- EMEA

The report, Global Myasthenia Gravis Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Flamel Technologies
- F. Hoffmann-La Roche
- Grifols
- Pfizer
- Shire
- Valeant Pharmaceuticals

Other prominent vendors
- Alexion Pharmaceuticals
- Catalyst Pharmaceuticals
- CSL
- Curavac
- Cytokinetics
- Galencia
- GlaxoSmithKline
- Lupin Pharmaceuticals
- Mitsubishi Tanabe Pharma
- Novartis

Market drivers
- Approval of novel monoclonal antibodies
- For a full, detailed list, view the full report

Market challenges
- Limited availability of approved drugs
- For a full, detailed list, view the full report

Market trends
- Emergence of new entrants
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Alexion Pharmaceuticals
  • CSL
  • Cytokinetics
  • Flamel Technologies
  • GlaxoSmithKline
  • Lupin Pharmaceuticals
  • MORE
Part 01: Executive summary

Part 02: Scope of the report
  • Market overview
  • Top-vendor offerings
Part 03: Market research methodology
  • Research methodology
  • Economic indicators
Part 04: Introduction
  • Key market highlights
  • Highlights
Part 05: Pipeline analysis

Part 06: Market landscape
  • Global myasthenia gravis drugs market
  • Five forces analysis
Part 07: Market segmentation by therapy area
  • Anticholinesterases
  • Immunosuppressants
  • IVIg
Part 08: Geographical segmentation
  • Myasthenia gravis drugs market in Americas
  • Myasthenia gravis drugs market in EMEA
  • Myasthenia gravis drugs market in APAC
Part 09: Market drivers
  • Approval of novel monoclonal antibodies
  • High unmet medical need
  • Growing research activities for the better understanding and diagnosis of myasthenia gravis
Part 10: Impact of drivers

Part 11: Market challenges
  • Presence of substitutes
  • Limited availability of approved drugs
  • Lack of long-term commitment
Part 12: Impact of drivers and challenges

Part 13: Market trends
  • Emergence of new entrants
  • Growing strategic acquisitions
  • Potential treatment options
Part 14: Vendor landscape
  • Competitive scenario
Part 15: Key vendor analysis
  • Flamel Technologies
  • F. Hoffmann-La Roche
  • Grifols
  • Pfizer
  • Shire
  • Valeant Pharmaceuticals
  • Other prominent vendors
Part 16: Appendix
  • List of abbreviations
Part 17: About the Author

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Key customer segments of global myasthenia gravis drugs market
Exhibit 03: Factors affecting the adoption rates of myasthenia gravis drugs market
Exhibit 04: Key pipeline candidates
Exhibit 05: Global myasthenia gravis drugs market snapshot
Exhibit 06: Analysis of global myasthenia gravis drugs market
Exhibit 07: Global myasthenia gravis drugs market 2016-2021 ($ millions)
Exhibit 08: Opportunity analysis of global myasthenia gravis drugs market
Exhibit 09: Opportunity analysis in developed and emerging markets
Exhibit 10: Five forces analysis
Exhibit 11: Segmentation of global myasthenia gravis drugs market by therapy
Exhibit 12: Segmentation of global myasthenia gravis drugs market based on geography 2016 and 2021
Exhibit 13: Global myasthenia gravis drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 14: Market scenario in Americas
Exhibit 15: Myasthenia gravis drugs market in Americas 2016-2021 ($ millions)
Exhibit 16: Market scenario in EMEA
Exhibit 17: Myasthenia gravis drugs market in EMEA 2016-2021 ($ millions)
Exhibit 18: Market scenario in APAC
Exhibit 19: Myasthenia gravis drugs market in APAC 2016-2021 ($ millions)
Exhibit 20: Key drivers and challenges in APAC
Exhibit 21: Key pipeline monoclonal antibodies
Exhibit 22: Incidence data for myasthenia gravis (annually)
Exhibit 23: Impact of drivers
Exhibit 24: Forcefield analysis of drivers and challenges
Exhibit 25: Impact of drivers and challenges
Exhibit 26: Key entrants in myasthenia gravis drugs market
Exhibit 27: Key acquisitions and their impact
Exhibit 28: Competitive structure analysis of global myasthenia gravis drugs market 2015
Exhibit 29: Competitive analysis of global myasthenia gravis drugs market
Exhibit 30: Market penetration of various myasthenia gravis manufacturers 2015
Exhibit 31: Flamel Technologies: Key highlights
Exhibit 32: Flamel Technologies: Strength assessment
Exhibit 33: Flamel Technologies: Strategy assessment
Exhibit 34: Flamel Technologies: Opportunity assessment
Exhibit 35: F. Hoffmann-La Roche: Strength assessment
Exhibit 36: F. Hoffmann-La Roche: Strategy assessment
Exhibit 37: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 38: F. Hoffmann-La Roche: Year-over-year (YoY) growth and revenue of MabThera/Rituxan 2013-2015 ($ billions)
Exhibit 39: F. Hoffmann-La Roche: Geographic segmentation of MabThera/Rituxan by revenue 2015
Exhibit 40: F. Hoffmann-La Roche: YoY growth and revenue of CellCept 2013-2015 ($ millions)
Exhibit 41: Grifols: Key highlights
Exhibit 42: Grifols: Strength assessment
Exhibit 43: Grifols: Strategy assessment
Exhibit 44: Grifols: Opportunity assessment
Exhibit 45: Pfizer: Strength assessment
Exhibit 46: Pfizer: Strategy assessment
Exhibit 47: Pfizer: Opportunity assessment
Exhibit 48: Pfizer: YoY and growth rate of Medrol 2013-2015 ($ millions)
Exhibit 49: Shire: Key highlights
Exhibit 50: Shire: Strength assessment
Exhibit 51: Shire: Strategy assessment
Exhibit 52: Shire: Opportunity assessment
Exhibit 53: Valeant Pharmaceuticals: Strength assessment
Exhibit 54: Valeant Pharmaceuticals: Strategy assessment
Exhibit 55: Valeant Pharmaceuticals: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Alexion Pharmaceuticals
  • CSL
  • Cytokinetics
  • Flamel Technologies
  • GlaxoSmithKline
  • Lupin Pharmaceuticals
  • MORE
New Report Released: - Global Myasthenia Gravis Drugs Market 2017-2021

The author of the report recognizes the following companies as the key players in the global myasthenia gravis drugs market: Flamel Technologies, F. Hoffmann-La Roche, Grifols, Pfizer, Shire, and Valeant Pharmaceuticals

Other Prominent Vendors in the market are: Alexion Pharmaceuticals, Catalyst Pharmaceuticals, CSL, Curavac, Cytokinetics, Galencia, GlaxoSmithKline, Lupin Pharmaceuticals, Mitsubishi Tanabe Pharma, and Novartis

Commenting on the report, an analyst from the research team said: “The high unmet medical need in the market has driven the emergence of new entrants, which are extensively conducting R&D activities to bring new products to the market. For instance, Curavac, Novartis, Cytokinetics, and Catalyst Pharmaceuticals are few of the potential vendors that are anticipating new approvals during the forecast period. Curavac is currently investigating CVMG101, an immunotherapy, for the potential treatment of myasthenia gravis. The drug candidate is in Phase Ib development stage. CVMG101 already received orphan drug designation from the US FDA and European Medicines Agency (EMA) in 2011 and 2009, respectively. Therefore, the product has an added advantage in gaining approval soon.”

According to the report, myasthenia gravis is the common disorder of neuromuscular transmission. The presence of large patient pool with myasthenia gravis is expected to fuel the market growth. The data estimates suggest that out of the existing patient pool in the US, approximately 15%-20% of people will experience a myasthenic crisis (a complication of myasthenia gravis resulting in severe muscle weakness, leading to respiratory failure). Three-fourths of these cases experience their first crisis within two years of diagnosis. Further, the disease is increasingly affecting the pediatric population, which will, in turn, increase the overall patient pool, thereby fueling the market growth. For instance, the incidence in the pediatric population is estimated to be between 1 and 5 cases per million. It is further estimated that between 10% and 15% of the myasthenia gravis cases occur in the pediatric population. Such rising cases with myasthenia gravis will certainly drive the market growth.

Further, the report states that the growing preference for substitutes such as thymectomy could hinder the growth prospects in the market. Thymectomy is mandatory in individuals with thymoma and is recommended as an alternative for non-thymomatous individuals with generalized myasthenia gravis. Particularly in individuals with acetylcholine antibodies and younger than 60 years, to enhance the likelihood of remission or improvement. Thymectomy therapy offers long-term benefit to an individual by reducing or stopping the existing chronic medical therapies. In addition, there has been growing support from healthcare organizations to opt for thymectomy. For instance, in August 2016, in a global study of myasthenia gravis (partially funded by National Institutes of Health), researchers found that surgical removal of thymus reduced individual's weakness and their need for immunosuppressive drugs. On an average, the researchers stated that the combination of surgery and prednisone treatment minimized overall muscle weakness greater than prednisone treatment alone. Although surgery is associated with higher costs, it could reduce the length of hospitalization. Further, thymectomy rarely causes any adverse effects. This indicates that surgery would affect the adoption rates of existing drugs in the market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Flamel Technologies
  • F. Hoffmann-La Roche
  • Grifols
  • Pfizer
  • Shire
  • Valeant Pharmaceuticals
  • Alexion Pharmaceuticals
  • Catalyst Pharmaceuticals
  • CSL
  • Curavac
  • Cytokinetics
  • Galencia
  • GlaxoSmithKline
  • Lupin Pharmaceuticals
  • Mitsubishi Tanabe Pharma
  • Novartis
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll